Dashboard
Company has a low Debt to Equity ratio (avg) at times
Low Debt Company with Strong Long Term Fundamental Strength
The company declared very negative results in Jan'25 after positive results in Oct'24
With ROE of 29.30%, it has a attractive valuation with a 1.85 Price to Book Value
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
USD 162 Million (Micro Cap)
6.00
NA
0.00%
0.39
17.97%
2.51
Total Returns (Price + Dividend) 
Kewaunee Scientific Corp. for the last several years.
Risk Adjusted Returns v/s 
News

Kewaunee Scientific Corp. Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics
Kewaunee Scientific Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation. The company exhibits strong financial metrics, including a P/E ratio of 6 and a return on equity of 29.30%, indicating effective management and a competitive position within its industry.
Read More
Kewaunee Scientific Corp. Forms Death Cross, Signals Bearish Trend Ahead
Kewaunee Scientific Corp. has recently encountered a Death Cross, indicating a potential shift in market sentiment. Technical indicators show a bearish outlook, despite a strong annual performance. Year-to-date, the company has faced a notable decline, contrasting with broader market gains, emphasizing its volatility and challenges ahead.
Read MoreIs Kewaunee Scientific Corp. technically bullish or bearish?
As of 11 September 2025, the technical trend for Kewaunee Scientific Corp. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by weekly and monthly MACD indicators both showing a mildly bearish signal, along with the Bollinger Bands indicating a mildly bearish trend on the weekly chart. The moving averages present a mildly bullish signal on the daily timeframe, but this is overshadowed by the overall bearish indicators. Additionally, the Dow Theory shows a mildly bearish stance on the monthly timeframe. In terms of performance, Kewaunee has outperformed the S&P 500 over the past week with a return of 5.85% compared to 1.05%, but it has underperformed over the longer periods, with a year-to-date return of -26.30% versus the S&P 500's 12.22%....
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jan 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 10 Schemes (15.6%)
Held by 14 Foreign Institutions (2.81%)
Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ
QoQ Growth in quarter ended Apr 2025 is 14.73% vs 40.59% in Jan 2025
QoQ Growth in quarter ended Apr 2025 is 250.00% vs -53.33% in Jan 2025
Annual Results Snapshot (Consolidated) - Apr'25
YoY Growth in year ended Apr 2025 is 18.01% vs -7.15% in Apr 2024
YoY Growth in year ended Apr 2025 is -39.27% vs 1,264.29% in Apr 2024






